KLK3 and cancer: Although 1st line treatment including androgen deprivation therapy (ADT) is initially highly effective in the relief of cancer-related symptoms, prostate-specific antigen (PSA) decline, and tumor shrinking, therapeutic resistance is almost universal, and most mCSPC progresses to castration-resistant prostate cancer (CRPC).